

Systemic anticancer therapy for advanced renal cell carcinoma: treatment options (intermediate or poor risk IMDC)

Base all treatment choices on [shared decision making](#). Think about enrolment into a clinical trial as an option at each step.

Initial recommended treatment options are the:

- [NICE technology appraisal guidance on cabozantinib with nivolumab](#) or
- [NICE technology appraisal guidance on lenvatinib with pembrolizumab](#) or
- [NICE technology appraisal guidance on nivolumab with ipilimumab](#) or
- [NICE technology appraisal guidance on avelumab with axitinib](#) (managed access through the Cancer Drugs Fund) or
- [NICE technology appraisal guidance on cabozantinib](#) or
- [NICE technology appraisal guidance on sunitinib](#) or
- [NICE technology appraisal guidance on pazopanib](#) or
- [NICE technology appraisal guidance on tivozanib](#).

Initial treatment with cabozantinib with nivolumab

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on cabozantinib with nivolumab](#), recommended treatment options are:

- the [NICE technology appraisal guidance on axitinib](#) or
- the [NICE technology appraisal guidance on lenvatinib with everolimus](#) or
- the [NICE technology appraisal guidance on everolimus](#) or
- the [NICE technology appraisal guidance on sunitinib](#) (NHS England Policy) or
- the [NICE technology appraisal guidance on pazopanib](#) (NHS England Policy) or
- the [NICE technology appraisal guidance on tivozanib](#) (NHS England Policy)
- nivolumab monotherapy (if cabozantinib is permanently discontinued due to toxicity and there is no evidence of progressive disease; NHS England Policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on cabozantinib with nivolumab](#) and have disease progression after treatment in line with the [NICE technology appraisal guidance on axitinib](#), the only recommended treatment option is the [NICE technology appraisal guidance on everolimus](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on cabozantinib with nivolumab](#) and have disease progression after treatment in line with the [NICE technology appraisal guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) (NHS England Policy), the only recommended treatment option is the [NICE technology appraisal guidance on everolimus](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on cabozantinib with nivolumab](#) and have disease progression after treatment with nivolumab monotherapy (because cabozantinib was permanently discontinued due to toxicity and there was no evidence of progressive disease; NHS England Policy), recommended treatment options are the:

- [NICE technology appraisal guidance on axitinib](#) or
- [NICE technology appraisal guidance on lenvatinib with everolimus](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on cabozantinib with nivolumab](#) who have disease progression after treatment with nivolumab monotherapy (because cabozantinib was permanently discontinued due to toxicity and there was no evidence of progressive disease; NHS England Policy) and disease progression after treatment in line with the [NICE technology appraisal guidance on axitinib](#), the only recommended treatment option is [NICE technology appraisal guidance on everolimus](#).

Initial treatment with lenvatinib with pembrolizumab

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on lenvatinib with pembrolizumab](#), recommended treatment options are the:

- [NICE technology appraisal guidance on cabozantinib](#) or
- [NICE technology appraisal guidance on everolimus](#) or

- [NICE technology appraisal guidance on axitinib](#) or
- [NICE technology appraisal guidance on sunitinib](#) (NHS England Policy) or
- [NICE technology appraisal guidance on pazopanib](#) (NHS England Policy) or
- [NICE technology appraisal guidance on tivozanib](#) (NHS England Policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on lenvatinib with pembrolizumab](#) and have disease progression after treatment in line with the [NICE technology appraisal guidance on cabozantinib](#), the only recommended treatment option is the [NICE technology appraisal guidance on everolimus](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on lenvatinib with pembrolizumab](#) and have disease progression after treatment in line with the [NICE technology appraisal guidance on everolimus](#), the only recommended treatment option is the [NICE technology appraisal guidance on cabozantinib](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on lenvatinib with pembrolizumab](#) and have disease progression after treatment in line with the [NICE technology appraisal guidance on axitinib](#), the only recommended treatment option is the [NICE technology appraisal guidance on everolimus](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on lenvatinib with pembrolizumab](#) and have disease progression after treatment in line with the [NICE technology appraisal guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) (NHS England Policy), recommended treatment options are the:

- [NICE technology appraisal guidance on cabozantinib](#) or
- [NICE technology appraisal guidance on everolimus](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on lenvatinib with pembrolizumab](#) who have disease progression after treatment in line with the [NICE technology appraisal guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) (NHS England Policy) and disease progression after

treatment in line with the [NICE technology appraisal guidance on cabozantinib](#), the only recommended treatment option is [NICE technology appraisal guidance on everolimus](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on lenvatinib with pembrolizumab](#) who have disease progression after treatment in line with the [NICE technology appraisal guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) (NHS England Policy) and disease progression after treatment in line with the [NICE technology appraisal guidance on everolimus](#), the only recommended treatment option is [NICE technology appraisal guidance on cabozantinib](#).

Initial treatment with nivolumab with ipilimumab

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on nivolumab with ipilimumab](#), recommended treatment options are the:

- [NICE technology appraisal guidance on cabozantinib](#) (NHS England Policy) or
- [NICE technology appraisal guidance on everolimus](#) or
- [NICE technology appraisal guidance on sunitinib](#) (NHS England Policy) or
- [NICE technology appraisal guidance on pazopanib](#) (NHS England Policy) or
- [NICE technology appraisal guidance on tivozanib](#) (NHS England Policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on nivolumab with ipilimumab](#) and have disease progression after treatment in line with the [NICE technology appraisal guidance on cabozantinib](#) (NHS England Policy), recommended treatment options are:

- [NICE technology appraisal guidance on lenvatinib with everolimus](#) or
- [NICE technology appraisal guidance on everolimus](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on nivolumab with ipilimumab](#) and have disease progression after treatment in line with the [NICE technology appraisal guidance on everolimus](#), the

only recommended treatment option is the [NICE technology appraisal guidance on cabozantinib](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on nivolumab with ipilimumab](#) and have disease progression after treatment in line with the [NICE technology appraisal guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) (NHS England Policy), recommended treatment options are:

- [NICE technology appraisal guidance on cabozantinib](#) or
- [NICE technology appraisal guidance on everolimus](#) or
- [NICE technology appraisal guidance on lenvatinib with everolimus](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on nivolumab with ipilimumab](#) who have disease progression after treatment in line with the [NICE technology appraisal guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) (NHS England Policy) and disease progression after treatment in line with the [NICE technology appraisal guidance on cabozantinib](#), the only recommended treatment option is [NICE technology appraisal guidance on everolimus](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on nivolumab with ipilimumab](#) who have disease progression after treatment in line with the [NICE technology appraisal guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) (NHS England Policy) and disease progression after treatment in line with the [NICE technology appraisal guidance on everolimus](#), the only recommended treatment option is [NICE technology appraisal guidance on cabozantinib](#).

Initial treatment with avelumab with axitinib

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on avelumab with axitinib](#) (managed access through the Cancer Drugs Fund), recommended treatment options are the:

- [NICE technology appraisal guidance on cabozantinib](#) or
- [NICE technology appraisal guidance on lenvatinib with everolimus](#) or
- [NICE technology appraisal guidance on everolimus](#) or

- [NICE technology appraisal guidance on sunitinib](#) (NHS England Policy) or
- [NICE technology appraisal guidance on pazopanib](#) (NHS England Policy) or
- [NICE technology appraisal guidance on tivozanib](#) (NHS England Policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on avelumab with axitinib](#) (managed access through the Cancer Drugs Fund) and have disease progression after treatment in line with the [NICE technology appraisal guidance on cabozantinib](#), the only recommended treatment option is the [NICE technology appraisal guidance on everolimus](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on avelumab with axitinib](#) (managed access through the Cancer Drugs Fund) and have disease progression after treatment in line with the [NICE technology appraisal guidance on lenvatinib with everolimus](#) or [everolimus](#), the only recommended treatment option is the [NICE technology appraisal guidance on cabozantinib](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on avelumab with axitinib](#) (managed access through the Cancer Drugs Fund) and have disease progression after treatment in line with the [NICE technology appraisal guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) (NHS England Policy), recommended treatment options are the:

- [NICE technology appraisal guidance on cabozantinib](#) or
- [NICE technology appraisal guidance on everolimus](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on avelumab with axitinib](#) (managed access through the Cancer Drugs Fund) who have disease progression after treatment in line with the [NICE technology appraisal guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) (NHS England Policy) and disease progression after treatment in line with the [NICE technology appraisal guidance on cabozantinib](#), the only recommended treatment option is the [NICE technology appraisal guidance on everolimus](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on avelumab with axitinib](#) (managed access through the Cancer Drugs

Fund) who have disease progression after treatment in line with the [NICE technology appraisal guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) (NHS England Policy) and disease progression after treatment in line with the [NICE technology appraisal guidance on everolimus](#), the only recommended treatment option is the [NICE technology appraisal guidance on cabozantinib](#).

Initial treatment with cabozantinib

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on cabozantinib](#), recommended treatment options are the:

- [NICE technology appraisal guidance on axitinib](#) or
- [NICE technology appraisal guidance on lenvatinib with everolimus](#) or
- [NICE technology appraisal guidance on everolimus](#) or
- [NICE technology appraisal guidance on nivolumab](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on cabozantinib](#) and have disease progression after treatment in line with the [NICE technology appraisal guidance on axitinib](#), recommended treatment options are the:

- [NICE technology appraisal guidance on everolimus](#) or
- [NICE technology appraisal guidance on nivolumab](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on cabozantinib](#) and have disease progression after treatment in line with the [NICE technology appraisal guidance on lenvatinib with everolimus](#) or [everolimus](#), the only recommended treatment option is the [NICE technology appraisal guidance on nivolumab](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on cabozantinib](#) and have disease progression after treatment in line with the [NICE technology appraisal guidance on nivolumab](#), recommended treatment options are the:

- [NICE technology appraisal guidance on axitinib](#) or

- [NICE technology appraisal guidance on lenvatinib with everolimus](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on cabozantinib](#) who have disease progression after treatment in line with the [NICE technology appraisal guidance on nivolumab](#) and disease progression after treatment in line with the [NICE technology appraisal guidance on axitinib](#), the only recommended treatment option is the [NICE technology appraisal guidance on everolimus](#).

Initial treatment with sunitinib, pazopanib or tivozanib

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#), recommended treatment options are the:

- [NICE technology appraisal guidance on cabozantinib](#) or
- [NICE technology appraisal guidance on axitinib](#) or
- [NICE technology appraisal guidance on lenvatinib with everolimus](#) or
- [NICE technology appraisal guidance on everolimus](#) or
- [NICE technology appraisal guidance on nivolumab](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) and have disease progression after treatment in line with the [NICE technology appraisal guidance on cabozantinib](#), recommended treatment options are the:

- [NICE technology appraisal guidance on everolimus](#) or
- [NICE technology appraisal guidance on nivolumab](#).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) and have disease progression after treatment in line with the [NICE technology appraisal guidance on axitinib](#), recommended treatment options are the:

- [NICE technology appraisal guidance on cabozantinib](#) or
- [NICE technology appraisal guidance on everolimus](#) or
- [NICE technology appraisal guidance on nivolumab](#).

1 For people who have had initial treatment in line with the [NICE technology appraisal](#)
2 [guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) who have disease progression after
3 treatment in line with the [NICE technology appraisal guidance on axitinib](#) and
4 disease progression after treatment in line with the [NICE technology appraisal](#)
5 [guidance on cabozantinib](#), the only recommended treatment option is the [NICE](#)
6 [technology appraisal guidance on everolimus](#).

7 For people who have had initial treatment in line with the [NICE technology appraisal](#)
8 [guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) who have disease progression after
9 treatment in line with the [NICE technology appraisal guidance on axitinib](#) and
10 disease progression after treatment in line with the [NICE technology appraisal](#)
11 [guidance on everolimus](#), the only recommended treatment option is the [NICE](#)
12 [technology appraisal guidance on cabozantinib](#).

13 For people who have had initial treatment in line with the [NICE technology appraisal](#)
14 [guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) and have disease progression after
15 treatment in line with the [NICE technology appraisal guidance on lenvatinib with](#)
16 [everolimus](#) or [everolimus](#), recommended treatment options are the:

- 17 • [NICE technology appraisal guidance on cabozantinib](#) or
- 18 • [NICE technology appraisal guidance on nivolumab](#).

19 For people who have had initial treatment in line with the [NICE technology appraisal](#)
20 [guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) and have disease progression after
21 treatment in line with the [NICE technology appraisal guidance on nivolumab](#),
22 recommended treatment options are the:

- 23 • [NICE technology appraisal guidance on cabozantinib](#) or
- 24 • [NICE technology appraisal guidance on lenvatinib with everolimus](#).

25 For people who have had initial treatment in line with the [NICE technology appraisal](#)
26 [guidance on sunitinib](#), [pazopanib](#) or [tivozanib](#) who have disease progression after
27 treatment in line with the [NICE technology appraisal guidance on nivolumab](#) and
28 disease progression after treatment in line with the [NICE technology appraisal](#)
29 [guidance on cabozantinib](#), the only recommended treatment option is the [NICE](#)
30 [technology appraisal guidance on everolimus](#).